Recursion Pharmaceuticals, Inc.
RXRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $5,175 | $19,103 | $14,745 | $4,511 |
| % Growth | -72.9% | 29.6% | 226.9% | – |
| Cost of Goods Sold | $29,593 | $20,161 | $21,829 | $12,794 |
| Gross Profit | -$24,418 | -$1,058 | -$7,084 | -$8,283 |
| % Margin | -471.8% | -5.5% | -48% | -183.6% |
| R&D Expenses | $121,062 | $128,636 | $129,634 | $98,334 |
| G&A Expenses | $41,628 | $46,653 | $54,650 | $77,186 |
| SG&A Expenses | $41,628 | $46,653 | $54,650 | $77,186 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$14,906 | -$120 | $0 | -$35 |
| Operating Expenses | $147,784 | $175,169 | $184,284 | $175,485 |
| Operating Income | -$172,202 | -$176,227 | -$191,368 | -$183,768 |
| % Margin | -3,327.6% | -922.5% | -1,297.9% | -4,073.8% |
| Other Income/Exp. Net | $9,952 | $4,330 | -$11,277 | $4,869 |
| Pre-Tax Income | -$162,250 | -$171,897 | -$202,645 | -$178,899 |
| Tax Expense | $3 | $0 | -$158 | $7 |
| Net Income | -$162,253 | -$171,897 | -$202,487 | -$178,906 |
| % Margin | -3,135.3% | -899.8% | -1,373.3% | -3,966% |
| EPS | -0.36 | -0.41 | -0.5 | -0.53 |
| % Growth | 12.2% | 18% | 5.7% | – |
| EPS Diluted | -0.36 | -0.41 | -0.5 | -0.53 |
| Weighted Avg Shares Out | 446,988 | 417,361 | 402,772 | 336,036 |
| Weighted Avg Shares Out Dil | 446,988 | 417,361 | 402,772 | 336,036 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $5,443 | $5,050 | $4,620 |
| Interest Expense | $0 | $480 | $0 | $605 |
| Depreciation & Amortization | $21,043 | $23,849 | $19,331 | $12,951 |
| EBITDA | -$141,207 | -$147,568 | -$182,806 | -$165,343 |
| % Margin | -2,728.6% | -772.5% | -1,239.8% | -3,665.3% |